{'fraction_non_alphanumeric': 0.0332512315270936, 'fraction_numerical': 0.023399014778325122, 'mean_word_length': 6.131578947368421, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Tumor prevention by a xanthate compound in experimental mouse‐skin tumorigenesis

The antiviral and antitumoral compound tricyclodecan‐9‐yl‐xanthogenate (D609), which is an inhibitor of protein kinase C activation, has been used for tumor prevention in vivo. When applied chronically together with 12‐O‐tetradecanoylphorbol‐13‐acetate (TPA) in the classic initiationpromotion mouse‐skin model, D609 prevented tumor induction in a dose‐dependent manner. At the concentration that inhibited tumor formation by 97%, no toxic effects were detected and the TPA‐induced hyperplasia remained unaffected. As D609 failed to prevent the activity of a chronically applied carcinogen, it is concluded that the observed tumor prevention achieved with D609 is tumor‐promotion‐specific and is not due to killing of tumor cells.